US4863713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and system for administering therapeutic and diagnostic agents
Assignee: University of California
•
Filing: 1986-06-23
•
Granted: 1989-09-05
•
Expires: 2006-06-23
Abstract
Abstract A method and system for localizing a diagnostic or therapeutic agent to an internal target site. The system includes (1) an epitopic compound, (2) a binding protein which is effective to bind specifically with the compound and capable of localizing selectively at the target tissue, when administered parenterally, and (3) a clearing agent which can bind to and cross-link the binding protein, to form a protein aggregate which is readily cleared from the subject's bloodstream. In practicing the method of the invention, the binding protein is administered to the subject parenterally, and allowed to localize at the target site, typically within 1-4 days. This is followed by a chase with the clearing agent to remove circulating, but not target-localized binding protein. When the epitopic compound is administered, binding of the compound to the localized binding protein, and rapid clearance of unbound compound by the kidneys, results in selective localization of the compound at the target site.
Inventors
- 👤 David A. Goodwin
- 👤 Claude Meares
- 👤 Michael McCall
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:09
CPC Classifications
B; B82; B82Y; B82Y5/00; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6891; A61K47/6897; A61K47/6898; A61K51/00; A61K51/02; A61K51/04; A61K51/08; A61K51/10; A61K51/1093; A61K2123/00
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
195 words
A method of localizing a diagnostic or therapeutic agent at an internal target site of a subject, said method comprising providing an epitopic compound which is composed of the agent to be targeted and an associated epitopic moiety, and which is rapidly cleared by the kidneys when administered parenterally, providing a binding protein capable of localizing selectively at the target tissue when administered to the subject parenterally, and effective to bind specifically to the epitopic compound at the target site, administering the binding protein parenterally, and allowing the protein to localize selectively at the target site, removing non-localized circulating binding protein by parenterally administering a clearing agent, which clearing agent is different from said epitopic compound, which clearing agent is capable of reacting with circulating binding protein to form a macromolecular aggregate which can be cleared rapidly by the subject's recticuloendothelial system, and after a period sufficient for removal of most of the circulating binding protein, administering the epitopic compound parenterally, whereby binding of the compound to the binding protein localized at the target site and rapid clearance of unbound compound by the kidneys results in selective localization of the compound at the target site.
Claim 2
Independent Claim
195 words
A method of localizing a diagnostic or therapeutic agent at an internal target site of a subject, said method comprising providing an epitopic compound which is composed of the agent to be targeted and an associated epitopic moiety, and which is rapidly cleared by the kidneys when administered parenterally, providing a binding protein capable of localizing selectively at the target tissue when administered to the subject parenterally, and effective to bind specifically to the epitopic compound at the target site, administering the binding protein parenterally, and allowing the protein to localize selectively at the target site, removing non-localized circulating binding protein by parenterally administering a clearing agent, which clearing agent is different from said epitopic compound, which clearing agent is capable of reacting with circulating binding protein to form a macromolecular aggregate which can be cleared rapidly by the subject's recticuloendothelial system, and after a period sufficient for removal of most of the circulating binding protein, administering the epitopic compound parenterally, whereby binding of the compound to the binding protein localized at the target site and rapid clearance of unbound compound by the kidneys results in selective localization of the compound at the target site.
Claim 3
Dependent Claim
17 words
The method of claim 1, wherein the binding protein is avidin and the epitopic moiety is biotin.
Claim 4
Dependent Claim
27 words
The method of claim 1, wherein the binding protein is an antibody, and the epitopic moiety is a haptenic moiety which is recognized immunospecifically by the antibody.
Claim 5
Dependent Claim
24 words
The method of claim 1, wherein the epitopic compound includes at least two epitopic moieties which are capable of binding to such binding protein.
Claim 6
Dependent Claim
45 words
The method of claim 1, for use in targeting the epitopic compound to a target tissue containing target-specific sites, wherein the binding protein contains at least one binding site specific against the epitopic compound, and at least one binding site specific against such target-specific sites.
Claim 7
Dependent Claim
40 words
The method of claim 1 for use in targeting the epitopic compound to a target tissue containing target-specific sites, wherein the binding protein is avidin covalently linked to at least one antibody fragment which is specific against such target-specific sites.
Claim 8
Dependent Claim
45 words
The method of claim 1, for use in administering the epitopic compound selectively at the site of a solid tumor, wherein the selectivity of binding protein localization is based on selective permeability of the protein across the walls of the capillaries which supply the tumor.
Claim 9
Dependent Claim
69 words
The method of claim 7, for localizing a radionuclide at such tumor site, wherein the epitopic compound is a radionuclide metal chelate of a 1-phenyl or 1-benzyl EDTA containing a parasubstituted spacer arm, the binding protein contains at least two binding sites which are specific against the compound, and the clearing agent is a macromolecule containing multiple binding sites which are capable of reacting specifically with the binding protein.
Claim 10
Dependent Claim
35 words
The method of claim 1, for use in delivering a radionuclide to the target site, wherein the epitopic compound is a epitope-chelate compound complexed with a metal ion to form a table metal chelate complex.
Claim 11
Dependent Claim
26 words
The method of claim 9, wherein the epitope-chelate compound is a metal chelate of a 1-phenyl or 1-benzyl EDTA having a parasubstituted epitope or chemical modification.
Claim 12
Dependent Claim
28 words
The method of claim 9, for use in treating a solid tumor, wherein said chelate compound is a metal chelate of 90 Y, 197 Hg or 67 Cu.
Claim 13
Dependent Claim
44 words
The method of claim 9, for use in radioimaging a body tumor, wherein said chelate compound is a metal chelate of 111 In, 67 Ga, 64 Cu, 99m Tc, 68 Ga, 62 Zn, 67 Cu, 197 Hg, 97 Ru, 57 Co, or 53 Co.
Claim 14
Dependent Claim
25 words
The method of claim 9, for use in radiosensitizing a body tumor, wherein said chelate compound is a metal chelate of iron, copper or ruthenium.
Claim 15
Independent Claim
121 words
A system for localizing a a diagnostic or therapeutic agent at an internal target site of a subject, comprising an epitopic compound which is composed of the agent to be localized and an associated epitopic moiety, and which is rapidly cleared by the kidneys when administered parenterally, a binding protein capable of localizing selectively at the target tissue when administered to the subject parenterally, and effective to bind specifically to the epitopic compound at the target site, and a clearing agent capable of reacting with said binding protein, with such circulating in the bloodstream of the subject, to form a macromolecular aggregate which is cleared rapidly by the subject's reticuloendothelial system, wherein said clearing agent is different from said epitopic compound.
Claim 16
Independent Claim
121 words
A system for localizing a a diagnostic or therapeutic agent at an internal target site of a subject, comprising an epitopic compound which is composed of the agent to be localized and an associated epitopic moiety, and which is rapidly cleared by the kidneys when administered parenterally, a binding protein capable of localizing selectively at the target tissue when administered to the subject parenterally, and effective to bind specifically to the epitopic compound at the target site, and a clearing agent capable of reacting with said binding protein, with such circulating in the bloodstream of the subject, to form a macromolecular aggregate which is cleared rapidly by the subject's reticuloendothelial system, wherein said clearing agent is different from said epitopic compound.
Claim 17
Dependent Claim
19 words
The system of claim 14, wherein the binding protein is avidin and the epitopic compound includes a biotin epitope.
Claim 18
Dependent Claim
27 words
The system of claim 14, wherein the binding protein is an antibody, and the epitopic compound includes a haptenic epitope which is recognized immunospecifically by the antibody.
Claim 19
Dependent Claim
23 words
The system of claim 14, wherein the epitopic compound includes at least two epitopes which are capable of binding to such binding proteins.
Claim 20
Dependent Claim
35 words
The system of claim 14, for use in delivering a radionuclide to the target site, wherein the epitopic compound is a epitope-chelate compound complexed with a metal ion to form a table metal chelate complex.
Claim 21
Dependent Claim
19 words
The system of claim 18, wherein the epitope-chelate compound is a metal chelate of a 1-phenyl or 1-benzyl EDTA.
Claim 22
Dependent Claim
22 words
The system of claim 19, wherein the epitope-chelate compound is a metal chelate having thiobutane spacer arm linked to the benzyl moiety.
References Cited (Backward Citations)
US3994966A
Cited
US3935074A
Cited
US4043998A
Cited
US4130462A
Cited
US4478815A
Cited
US4339426A
Cited
US4699877A
Cited
US4741900A
Cited
US4624846A
Cited
US4634586A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-04 | 1993-03-06 | 1993-09-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-04 | 1997-03-06 | 1997-09-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-04 | 2001-03-06 | 2001-09-05 | $7700.00 | Window Closed / Lapsed |